Determining CLL Risks and Treatment Options
- CLL behaves differently for everyone, and some people may never need treatment. Doctors now look closely at the biology of your CLL — not just what shows up on an exam — to understand how your disease is likely to act over time.
- Certain lab markers help predict what to expect, like IGHV status, TP53 mutations, and CD49D. Some markers point to slower‑moving CLL, while others signal higher‑risk disease that may not respond as well to standard treatments.
- Outcomes vary widely, from decades without needing therapy to more aggressive disease — but even high‑risk patients have options, including advanced treatments like CAR T‑cell therapy or stem cell transplant.
Dr. Vikas Bhushan, a hematologist-oncologist with Texas Oncology at Medical City Dallas, explains to SurvivorNet that genetic markers can help doctors identify people whose CLL may remain stable for years — sometimes decades — as well as those with a more aggressive form of the disease who may need treatment sooner.
Read MoreFrom Staging Alone to Biology-Driven Risk Assessment
For decades, doctors classified CLL almost entirely using two staging systems — the Rai system and the Binet system — which assess factors such as blood counts, lymph node swelling, and organ involvement to estimate disease progression.“In the old days, we went mainly by the stage — two types of staging,” Dr. Bhushan said. “But now, the biologic parameters are more important, and that determines how well the patient will do long-term.”
(The Binet system is more often used in Europe.) The stages are broken up into early-stage (stages zero, 1, and 2) and advanced (stages 3 and 4). Early in the disease, the lymphocyte count is high, and the lymph nodes, liver, and spleen may be affected to varying degrees.
Expert Resources for CLL Patients
- CLL Treatment: The Side Effects to Expect & Why Reporting All New Symptoms is Crucial
- After the Initial CLL Diagnosis: The First Conversation
- BTK Inhibitors Play An Important Role In CLL Treatment & Management
- BTK Inhibitors: Finding The Right Fit For Chronic Lymphocytic Leukemia (CLL) Patients
- Chronic Lymphocytic Leukemia (CLL): How Can Pirtobrutinib Fit Into My Treatment Plan?
- Determining Your CLL Treatment: Why Stage Is Only Part of the Picture
The CLL International Prognostic Index (CLL-IPI)
Dr. Bhushan referenced a newer tool doctors use to estimate prognosis: the CLL International Prognostic Index, or CLL-IPI, which helps predict time to first treatment in early CLL. CLL-IPI combines five factors — age, clinical stage, TP53 mutation status (normal vs. deletion of chromosome 17p and/or a TP53 mutation), IGHV mutational status, and serum β2-microglobulin — to estimate survival and time to first treatment in CLL patients.
IGHV status alone is also one of the most useful tools doctors use to help choose a treatment approach: patients with a mutated IGHV gene tend to have slower-growing disease and generally stay in remission longer than patients with unmutated IGHV, though exactly how much longer depends heavily on which treatment is used.
Dr. Bhushan singled out TP53 mutations as “a main driver” of poor prognosis in CLL, noting that patients with TP53 mutations or deletions tend to have worse outcomes and don’t respond as well to standard treatment.
CD49D, a protein some doctors test for when assessing prognosis, is a lesser-known but still meaningful prognostic marker, and Dr. Bhushan says it’s typically assessed alongside IGHV mutation status.
A Wide Range of Outcomes — and Options for High-Risk Patients
Dr. Bhushan emphasized that biology, not just a diagnosis of CLL, determines the outlook. Patients with favorable markers may go decades without their disease ever requiring aggressive treatment.
“The patient with good markers may go on for 25, 30 years,” he said, noting that with “a small percentage of patients — the disease never progresses.”
On the other end of the spectrum, Dr. Bhushan noted that younger patients with high-risk disease can still do poorly despite standard treatment — but that doesn’t mean they’re out of options. “You can do CAR T-cell or stem cell transplant — and those patients can also have a good outcome.”
Learn more about SurvivorNet's rigorous medical review process.
